AdachiN, FenwickP, AkanumaN, HaraK, IshiiR, OkazakiM, ItoM, SekimotoM, KatoM, OnumaT: Increased frequency of psychosis after second-generation antiepileptic drug administration in adults with focal epilepsy. Epilepsy Behav, 97:138–143, 2019.
2.
AdanRAH: Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci, 36:133–140, 2013.
3.
BarkerMK, SableCM, MontgomerySE, ChowL, GreenTJ, PanagiotopoulosC, DevlinAM: Diet and cardiometabolic side effects in children treated with second-generation antipsychotics. Clin Nutr ESPEN, 23:205–211, 2018.
4.
BarzmanDH, DelBelloMP, KowatchRA, WarnerJ, RofeyD, StanfordK, RappaportK, DanielsJP, StrakowskiSM: Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol, 15:931–937, 2005.
5.
BerlinH: Antiepileptic drugs for the treatment of impulsivity. Curr Psychiatry Rev, 4:114–136, 2008.
6.
ChungST, OnuzuruikeAU, MaggeSN: Cardiometabolic risk in obese children. Ann N Y Acad Sci, 1411:166–183, 2018.
7.
CoomansCP, GeerlingJJ, van den BergSAA, van DiepenHC, Garcia-TardónN, ThomasA, Schröder-van der ElstJP, OuwensDM, PijlH, RensenPCN, HavekesLM, GuigasB, RomijnJA: The insulin sensitizing effect of topiramate involves K ATP channel activation in the central nervous system. Br J Pharmacol, 170:908–918, 2013.
8.
CorrellCU, SikichL, ReevesG, JohnsonJ, KeetonC, SpanosM, KapoorS, BussellK, MillerL, ChandrasekharT, SheridanEM, PirmohamedS, ReinblattSP, AldermanC, ScheerA, BornerI, BetheaTC, EdwardsS, HamerRM, RiddleMA: Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: Results from the IMPACT trial. World Psychiatry, 19:69–80, 2020.
9.
CzepielKS, PerezNP, Campoverde ReyesKJ, SabharwalS, StanfordFC: Pharmacotherapy for the treatment of overweight and obesity in children, adolescents, and young adults in a large health system in the US. Front Endocrinol (Lausanne), 11:290, 2020.
10.
DavissWB, BarnettE, NeubacherK, DrakeRE: Use of antipsychotic medications for nonpsychotic children: Risks and implications for mental health services. Psychiatr Serv, 67:339–341, 2016.
11.
DayabandaraM, HanwellaR, RatnatungaS, SeneviratneS, SuraweeraC, de SilvaV: Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat, 13:2231–2241, 2017.
EllingerLK, IpemaHJ, StachnikJM: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother, 44:668–679, 2010.
14.
EllulP, DelormeR, CorteseS: Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: A systematic review and meta-analysis. CNS Drugs, 32:1103–1112, 2018.
15.
MarangoniC, De ChiaraL, FaeddaGL: Bipolar disorder and ADHD: Comorbidity and diagnostic distinctions. Curr Psychiatry Rep, 17:604, 2015.
16.
MasiG, SessoG, PfannerC, ValenteE, MolestiA, PlaciniF, BoldriniS, LoriauxN, DragoF, MontesantoAR, PisanoS, MiloneA: An exploratory study of emotional dysregulation dimensions in youth with attention deficit hyperactivity disorder and/or bipolar spectrum disorders. Front Psychiatry 12, 2021.
17.
MoaveroR, SantaroneME, GalassoC, CuratoloP: Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy. Brain Dev, 39:464–469, 2017.
18.
MunshiKR, OkenT, GuildDJ, TrivediHK, WangBC, DucharmeP, Gonzalez-HeydrichJ: The use of antiepileptic drugs (AEDs) for the treatment of pediatric aggression and mood disorders. Pharmaceuticals (Basel), 3:2986–3004, 2010.
19.
NikouAF, LaiM, SolmssenC, BhargavaM, Ben-DavidK, RamsubickC, RiceT, CoffeyB: Topiramate for posttraumatic symptoms in an obese adolescent girl. J Child Adolesc Psychopharmacol, 31:235–241, 2021.
20.
RiceTR, WaltherA: Male-specific metabolic considerations concerning the prescription of second-generation antipsychotics to adolescents. J Child Adolesc Psychopharmacol, 31:53–55, 2020.
21.
SimonettiA, KoukopoulosAE, KotzalidisGD, JaniriD, De ChiaraL, JaniriL, SaniG: Stabilization beyond mood: Stabilizing patients with bipolar disorder in the various phases of life. Front Psychiatry, 11:247, 2020.
22.
SinghT: Pediatric bipolar disorder: Diagnostic challenges in identifying symptoms and course of illness. Psychiatry (Edgmont), 5:34–42, 2008.
23.
SmithC, MylesH, GalletlyC: Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk. Australas Psychiatry, 25:387–390, 2017.
24.
StanleyBG: GABA: A cotransmitter linking leptin to obesity prevention. Endocrinology, 153:2057–2058, 2012.
25.
WróbelMP, MarekB, KajdaniukD, RokickaD, Szymborska-KajanekA, StrojekK: Metformin—A new old drug. Endokrynol Pol, 68:482–496, 2017.
26.
ZhuoC, XuY, LiuS, LiJ, ZhengQ, GaoX, LiS, JingR, SongX, YueW, ZhouC, UpthegroveR: Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: A systematic review and network meta-analysis. Front Pharmacol, 9:1393, 2018.